4th Quarter - Report

EMD SERONO, INC. for EMD SERONO INC

Period 4th Quarter 2019 Filed Jan 21, 2020 Signed by Wendy Sussman, Vice President, U.S. Healthcare Government & Public Affairs

Official filing
Firm
EMD SERONO, INC.
Client
EMD SERONO INC
Income
—
Expenses
$380,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

12 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

H.R. 3: Lower Drug Costs Now Act of 2019; all provisions of the bill H.R. 1046: Medicare Negotiation and Competitive Licensing Act of 2019; all provisions of the bill S. 2543: Prescription Drug Pricing Reduction Act of 2019; all provisions of the bill

LobbyistCovered position, as disclosed
THOMAS CORDREY ROBERGE —
WENDY SUSSMAN —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Environmental Protection Agency (EPA); SENATE; Executive Office of the President (EOP)

Bills named: H.R. 3 (116th), H.R. 1046 (116th), S. 2543 (116th)

Labor Issues/Antitrust/Workplace LBR

General discussions regarding workplace development

LobbyistCovered position, as disclosed
STEPHANIE FRYE (FORMERLY SALVAGNO) —

Contacted: Environmental Protection Agency (EPA); SENATE; HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); Food & Drug Administration (FDA)

Tariff (miscellaneous tariff bills) TAR

General discussions regarding the 2020 Miscellaneous Tariff Bill (MTB) process

LobbyistCovered position, as disclosed
STEPHANIE FRYE (FORMERLY SALVAGNO) —

Contacted: Environmental Protection Agency (EPA); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Taxation/Internal Revenue Code TAX

H.R. 1865: Further Consolidated Appropriations Act, 2020; provisions related to the using of PFAS chemicals in military fire fighting foams General discussions regarding the repeal of Internal Revenue Code Section 385 regulations

LobbyistCovered position, as disclosed
STEPHANIE FRYE (FORMERLY SALVAGNO) —

Contacted: Executive Office of the President (EOP); SENATE; HOUSE OF REPRESENTATIVES; Environmental Protection Agency (EPA); Food & Drug Administration (FDA)

Bills named: H.R. 1865 (116th)

Trade (domestic/foreign) TRD

General discussions regarding United States-Switzerland Free Trade Agreement General discussions regarding United States-European Union Free Trade Agreement General discussions regarding Section 301 tariffs and product exclusions applications

LobbyistCovered position, as disclosed
STEPHANIE FRYE (FORMERLY SALVAGNO) —

Contacted: Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Environmental Protection Agency (EPA); Food & Drug Administration (FDA); SENATE

Copyright/Patent/Trademark CPT

S. 1416: Affordable Prescriptions for Patients Act of 2019; all provisions of the bill

LobbyistCovered position, as disclosed
THOMAS CORDREY ROBERGE —
WENDY SUSSMAN —

Contacted: Food & Drug Administration (FDA); Environmental Protection Agency (EPA); SENATE; HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP)

Bills named: S. 1416 (116th)

Health Issues HCR

H.R. 3: Lower Drug Costs Now Act of 2019; all provisions of the bill H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019; all provisions of the bill H.R. 1046: Medicare Negotiation and Competitive Licensing Act of 2019; all provisions of the bill H.R. 1865: Further Consolidated Appropriations Act, 2020; provisions related to Division N, Title I H.R. 2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act; all provisions of the bill H.R. 2296: More Efficient Tools to Realize Information for Consumers (METRIC) Act; all provisions of the bill S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019; all provisions of the bill S. 1895: Lower Health Care Costs Act; all provisions of the bill S. 2543: Prescription Drug Pricing Reduction Act of 2019; all provisions of the bill (Draft) 21st Century Cures Act 2.0; all provisions of the draft General discussions regarding support for, and importance of, care giving

LobbyistCovered position, as disclosed
THOMAS CORDREY ROBERGE —
WENDY SUSSMAN —

Contacted: SENATE; Executive Office of the President (EOP); Food & Drug Administration (FDA); Environmental Protection Agency (EPA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 2113 (116th), H.R. 965 (116th), H.R. 2296 (116th), S. 340 (116th), H.R. 3 (116th), H.R. 1046 (116th), S. 2543 (116th), S. 1895 (116th), H.R. 1865 (116th)

Chemicals/Chemical Industry CHM

H.R.535: PFAS Action Act of 2019; provisions related to Polyfouroalyl/Perflourooctanesulfonic Acid (PFAS/PFOS) General discussions regarding the Toxic Substances Control Act; provisions related to Section 5 Discussions pertaining to comments regarding labeling of combination sunscreen/insect repellent products

LobbyistCovered position, as disclosed
STEPHANIE FRYE (FORMERLY SALVAGNO) —

Contacted: HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); SENATE; Food & Drug Administration (FDA); Environmental Protection Agency (EPA)

Bills named: H.R. 535 (116th)

Food Industry (safety, labeling, etc.) FOO

Discussions pertaining to comments regarding labeling of combination sunscreen/insect repellent products

LobbyistCovered position, as disclosed
STEPHANIE FRYE (FORMERLY SALVAGNO) —

Contacted: Executive Office of the President (EOP); SENATE; Environmental Protection Agency (EPA); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Animals ANI

General discussions regarding Predictive Toxicology Roadmap and 21st Century Cures Act 2.0 (Draft; all provisions of the Draft)

LobbyistCovered position, as disclosed
STEPHANIE FRYE (FORMERLY SALVAGNO) —

Contacted: Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); Environmental Protection Agency (EPA)

Pharmacy PHA

H.R. 3: Lower Drug Costs Now Act of 2019; all provisions of the bill H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019; all provisions of the bill H.R. 1865: Further Consolidated Appropriations Act, 2020; provisions related to Division N, Title I H.R. 2113: Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act; all provisions of the bill H.R. 2296: More Efficient Tools to Realize Information for Consumers (MICRA) Act; all provisions of the bill S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019; all provisions of the bill S. 474: Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019; all provisions of the bill S. 1416 - Affordable Prescriptions for Patients Act of 2019; all provisions of the bill S. 1895: Lower Health Care Costs Act; all provisions of the bill S. 2543: Prescription Drug Pricing Reduction Act of 2019; all provisions of the bill

LobbyistCovered position, as disclosed
THOMAS CORDREY ROBERGE —
WENDY SUSSMAN —

Contacted: Environmental Protection Agency (EPA); Executive Office of the President (EOP); SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Bills named: H.R. 2113 (116th), S. 1895 (116th), S. 474 (116th), H.R. 965 (116th), S. 2543 (116th), S. 340 (116th), H.R. 3 (116th), H.R. 2296 (116th), H.R. 1865 (116th), S. 1416 (116th)

Medical/Disease Research/Clinical Labs MED

H.R. 1865: Further Consolidated Appropriations Act, 2020; provisions related to the using of PFAS chemicals in military fire fighting foams

LobbyistCovered position, as disclosed
STEPHANIE FRYE (FORMERLY SALVAGNO) —

Contacted: Food & Drug Administration (FDA); Executive Office of the President (EOP); SENATE; HOUSE OF REPRESENTATIVES; Environmental Protection Agency (EPA)

Bills named: H.R. 1865 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.